The results will be presented in the following three sections: Section 1: Evidence from animal studies on the impact of GLP-1 RAs on intestinal inflammation in experimental colitis; Section 2: Evidence from human clinical studies on the effects of GLP-1 RAs in modulating IBD outcomes; Section 3: Evidence from human in vitro and clinical studies on the effect of GLP-1 RAs on disease activity in non-IBD immune-mediated inflammatory diseases (IMIDs). Here, GCG is linked to inflammatory bowel disease.